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Abstract
Rift Valley fever is a mosquito-borne zoonotic disease that affects both ruminants and humans. The nonstructural (NS)
protein, which is a major virulence factor for Rift Valley fever virus (RVFV), is encoded on the S-segment. Through the
cullin 1-Skp1-Fbox E3 ligase complex, the NSs protein promotes the degradation of at least two host proteins, the TFIIH
p62 and the PKR proteins. NSs protein bridges the Fbox protein with subsequent substrates, and facilitates the transfer of
ubiquitin. The SAP30-YY1 complex also bridges the NSs protein with chromatin DNA, affecting cohesion and segregation
of chromatin DNA as well as the activation of interferon-β promoter. The presence of NSs filaments in the nucleus
induces DNA damage responses and causes cell-cycle arrest, p53 activation, and apoptosis. Despite the fact that NSs
proteins have poor amino acid similarity among bunyaviruses, the strategy utilized to hijack host cells are similar. This
review will provide and summarize an update of recent findings pertaining to the biological functions of the NSs protein
of RVFV as well as the differences from those of other bunyaviruses.
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Background
Rift Valley fever (RVF) is a zoonotic viral disease transmit-
ted by mosquitoes. It was first identified in Kenya in 1930
[1], and has been endemic in sub-Saharan Africa for more
than 80 years [2]. Outbreaks of RVF have also occurred in
Madagascar, Egypt, Saudi Arabia, and Yemen, probably
through infected animals or mosquitoes [2–6]. The largest
recorded RVF outbreak occurred in Egypt back in 1977–78,
where there were an estimate of 20,000 to 200,000 human
cases and roughly 600 confirmed deaths [5]. The disease is
caused by the Rift Valley fever virus (RVFV), which belongs
to the genus Phlebovirus within the family Bunyaviridae
[7]. Pregnant cattle, goats, and especially sheep, are highly
susceptible to RVFV, resulting in fetal malformation (e.g.,
hydrop amnii, arthrogryposis, scoliosis, hydraencephaly,
cerebellar hypoplasia) and abrupt abortion in 40 to 100 %
of pregnant ewes [2, 8]. Newborn lambs are also highly sus-
ceptible to RVFV, and the mortality rate is estimated to be
95 to 100 % [2]. In adult ruminants, transient fever and
viremia are generally displayed and the mortality rate of
infected sheep has been documented to be up to 20 % [9].
Most human cases are characterized with self-limiting
febrile illness, and less than 8 % of patients develop a more
severe form of the disease, such as hemorrhagic fever,
encephalitis, or retinitis. The overall mortality rate for RVF
patients is 0.5 to 1 % [10–12]. Through vertical transmis-
sion, flood water Aedes mosquitoes play an important role
in the maintenance of RVFV in nature [13, 14]. Periods of
heavy rainfall generates ideal conditions for the hatching of
infected Aedes eggs [13], thus triggering the transmission
of RVFV to animals. Transmission of the disease to
humans (e.g., veterinarian, farmers, or abattoir workers)
can then be accomplished through direct contact with
bodily fluids derived from infected animals. However,
during an outbreak, infected mosquito vectors, such as
Culex pipiens, could also play an important role in RVFV
transmission to humans [14, 15]. Potential spread of RVFV,
either naturally or intentionally, into non-endemic coun-
tries is a major public health concern. Due to a concern
towards bioterrorism in the U.S., RVFV is classified as
Category A Priority Pathogen (NIAID/NIH), and an
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overlap select agent (U.S. Department of Human Health
Services, and U.S. Department of Agriculture). A strict
quarantine system is important to prevent the importation
of RVFV infected animals [16]. However, the case is not
the same for humans, because infected patients can travel
by airplanes, and may bring RVFV from endemic coun-
tries into non-endemic area [17]. Fortunately, human to
human transmission has not been documented and unin-
fected individuals are unlikely able to trigger RVF out-
breaks. Currently, there are no licensed RVF vaccines for
humans, and only a few licensed vaccines are available for
animals [18], such as the live-attenuated MP-12 vaccine,
which is conditionally licensed in the U.S. [19]. No effect-
ive therapeutic is available for RVF patients. Reduction of
viral load with increased survival rate was shown in mice
or nonhuman primates infected with RVFV through daily
post-exposure treatment with ribavirin (a guanosine ana-
log), Poly (ICLC) (a polyriboinosinic-polyribocytidylic acid
stabilized with poly-L-lysine and carboxymethyl cellulose),
recombinant IFN-αA or human IFN-α [20–25]. However,
both ribavirin and IFN-α have side effects associated with
therapeutic use [26]. Improvement of antivirals that is not
only effective for RVFV, but for other pathogenic bunya-
viruses, could be important countermeasures against the
threat that bunyaviruses impose. Currently, the challenge
lies within the development of broadly-active antivirals or
vaccines that can encompass the large genetic diversity of
bunyaviruses.
The bunyavirus genome is comprised of three negative-
sense single stranded RNA segments; Large (L)-, Medium
(M)-, and Small (S)-segments. The L-segment encodes
the RNA-dependent RNA polymerase (L protein). The
M-segment encodes a single open reading frame (ORF)
for glycoprotein precursor gene that produces the enve-
lope glycoproteins; Gn and Gc. The S-segment encodes
for the nucleoprotein (N protein). A nonstructural pro-
tein, NSm, is encoded in the M-segment of orthobunya-
viruses, nairoviruses, tospoviruses, or sandfly or
mosquito-borne phleboviruses, while NSs protein is
encoded in the S-segment of orthobunyaviruses, phlebo-
virues, nairovirus, or hantaviruses that are transmitted by
Arvicolinae or Sigmodontinae rodents, but not by muri-
nae rodents [7, 27–31].
Termini on the viral genome RNA are complementary
and forms a pan-handle structure, which serves as sig-
nals for N protein encapsidation and RNA synthesis [7].
Bunyavirus L proteins cleave capped host mRNA to ini-
tiate the synthesis of viral mRNA [32–35]. This cap-
snatching mechanism is also commonly used in other
segmented negative-stranded RNA viruses (e.g., influ-
enza viruses, and arenaviruses). The transcription of
bunyavirus mRNA is terminated within the untranslated
region (UTR) [36–40], while L protein do not recognize
the termination signal during the mode of viral genomic
RNA synthesis. The mechanism of transcription and gen-
ome replication, however, remains largely unknown.
RVFV M-segment encodes two precursor proteins,
78kD-Gc and NSm-Gn-Gc, for the expression of 78kD,
NSm, Gn, and Gc proteins through co-translational cleav-
age of precursor protein via signal peptidases [41]. The
78kD protein is a structural protein that is incorporated
into virions matured from mosquito cells, but not those
from Vero cells [42]. The 78kD protein is important for
efficient viral dissemination in mosquitoes [43–45],
while the NSm protein localizes to the mitochondrial
outer membrane, and delays apoptosis in mammalian
cells [46, 47].
Genetic diversity among bunyaviruses
The Bunyaviridae family consists of more than 350 dis-
tinct viruses, and belongs to the genus Orthobunyavirus,
Phlebovirus, Nairovirus, Hantavirus, and Tospovirus [7].
Phleboviruses consists of at least 70 named viruses, and
is divided into two antigenic groups; the sandfly fever
group, and the Uukuniemi group, which is based on the
presence of the preglycoprotein coding region in the M-
segment [48]. Traditionally phlebovirus species were de-
fined by the distinct antigenic cross-reactivity, however,
some phleboviruses do not form clear plaques in mamma-
lian cells, and the antigenic cross-reactivity has not been
well characterized. A number of viruses have not been
approved as phlebovirus species partly due to such tech-
nical inconvenience. Phleboviruses are currently comprised
of the following genetically distinct groups (Fig. 1); (i) sand-
fly or mosquito-borne phleboviruses; Rift Valley fever
group, Sandfly fever Naples group (e.g., Toscana virus:
TOSV), Sandfly fever Sicilian group (e.g., Sandfly fever Si-
cilian virus: SFSV), Joa group (e.g., Frijoles virus: FRIV), Sal-
obo group (e.g., Icoaraci virus: ICOV, Belterra virus),
Candiru group (e.g., Candiru virus, Alenquer virus, Itaituba
virus), Punta Toro group (e.g., Punta Toro virus: PTV),
Salehabad group (e.g., Salehabad virus, Arumowot virus),
and Aguacate group (e.g., Aguacate virus), (ii) tick-borne
phleboviruses; Uukuniemi group (e.g., Uukuniemi virus:
UUKV), Bhanja group (e.g., Bhanja virus, Kismayo virus),
Kaisodi group (e.g., Kaisodi virus, Lanjan virus), and Severe
Fever with Thrombocytopenia Syndrome (SFTS) and
Heartland group (e.g., SFTSV, Heartland virus). Sandfly
fever is characterized by a self-limiting febrile illness in
humans, whereas TOSV is known to cause aseptic menin-
gitis or meningoencephalitis [49, 50]. Most sandfly fever
viruses are transmitted by sandfly species within genus
Phlebotomus (old world sandflies: Sandfly fever Naples
group, Sandfly fever Sicilian group, and Salehabad group)
or genus Lutzomya (new world sandflies: Punta Toro
group, Joa group, Salobo group, Aguacate group, Joa
group, and Candiru group). On the other hand, RVFV,
ICOV, Arumowot virus, and Itaporanga virus (this virus
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still remains to be grouped) transmitted by mosquitoes [51].
SFTSV is transmitted by ticks (Haemaphysalis longicornis or
Rhipicephalus microplus) in China, and the disease is char-
acterized by an acute onset of fever, accompanied by
thrombocytopenia, leukopenia, and diarrhea in humans,
with the mortality rate of 12 to 30 % [52, 53]. Patients with
SFTSV were also identified in Korea and Japan [52–55].
Heartland virus is transmitted by lone star ticks (Amblymma
americanum) in the U.S., and the disease is characterized
with the onset of fevers with thrombocytopenia and
leukopenia [56].
The NSs protein is considered to be the major virulence
factor for bunyaviruses, and plays an important role in
viral evasion from the host innate immunity. It is import-
ant to characterize common biological functions of bunya-
virus NSs proteins toward the development of effective
therapeutic regimens and vaccines. However, NSs proteins
exhibit a wide diversity of amino acid sequences among
sandfly fever phleboviruses [57, 58]. For example, the
amino acid identities of NSs proteins among RVFV, SFSV,
TOSV, PTV, ICOV, and FRIV are low, and range from 7.5
to 28.6 % [57]. Although phleboviruses are genetically di-
verse, identification of common mechanisms utilized by
phlebovirus NSs proteins may lead to the development of
broadly-active antiviral molecules. We will describe the
current understanding of RVFV NSs functions, as well as
discuss the similarities and differences observed in NSs
proteins of other bunyaviruses in following sections.
Inhibition of host general transcription by
bunyavirus NSs proteins
RVFV NSs proteins are present in both the nucleus and
cytoplasm of infected cells, and it forms a filamentous
structure in nucleus [59]. The NSs protein of RVFV is
comprised of 265 amino acids (aa.) and is estimated to
be 31kD in size [7]. The 17aa. at the C-terminus is highly
acidic, and is responsible for the formation of the fila-
mentous structure seen in the nucleus [59]. Currently, no
nuclear localization signal for RVFV NSs protein has been
identified, however, nuclear accumulation of RVFV NSs
protein has been shown to be dependent on PXXP motifs
(P: proline, X: any amino acid) [60]. RVFV NSs protein
also encodes the FVEV (ΩXaV motif: Ω, omega: Trp or
Phe, X: any amino acid, a: Asp or Glu, V: Val) within the
last 17 amino acids of the C-terminus. Recombinant
RVFV encoding NSs lacking the ΩXaV motif, failed to
form NSs filaments in the nucleus, indicating the role of
ΩXaV motif in filament formation [61].
Le May et al. demonstrated that RVFV NSs protein in-
hibits cellular general transcription activity by directly inter-
acting with transcription factor (TF) IIH components [62].
The TFIIH is comprised of ten subunits; i.e., (i) the core
complex: XPB, XPD, p52, p44, p62, p34, and p8, and (ii)
the cyclin activating kinase sub-complexes: cdk7, cyclin H,
and MAT1. As one of the basal transcription factors, TFIIH
along with TFIIA, TFIIB, TFIID, TFIIE, and TFIIF, forms
the transcription preinitiation complex for RNA polymer-
ase II. TFIIH is involved in promoter melting and allowing
Pol-II to escape from the promoter to transition from the
initiation complex to the elongation complex via cyclin-
dependent phosphorylation of the Pol-II large subunit C-
terminal domain (CTD). TFIIH is also required for RNA
polymerase I-mediated transcription [63]. Synthesis of both
poly-A(+) and poly-A(−) RNA was decreased in the pres-
ence of RVFV NSs protein. The XPB and p44 subunit was
shown to co-localize with RVFV NSs filaments, unlike p62,
p52, cdk7, and XPD, which did not. It was also observed
that XPD and p62 proteins were decreased in the presence
of NSs proteins, whereas the p44, XPB, and TBP (TATA-
binding protein) did not. NSs proteins bound to p44, but
Fig. 1 Genetic diversity of phleboviruses. Phylogenetic analysis of available phlebovirus M-segment partial ORF (corresponding to RVFV M precursor
polyprotein amino acid position 583 to 770) at amino acid level was performed. The neighbor-joining method with Kimura two-parameter distance
was utilized to generate phylogenetic tree with 1000 replicates, using CLC Genomics Workbench version 7.5.2. Vectors and isolations of each virus are
also shown. Relevant studies have been reported previously [51, 57, 141–148]
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not directly to XPB. The NSs protein did not interact with
p44 subunits that had been already incorporated into the
TFIIH complex. From what had been gathered, it was hy-
pothesized that RVFV NSs protein competes for the bind-
ing between XPD and p44, thus preventing the assembly of
the TFIIH complex in the nucleus.
In later studies, Kalveram et al. demonstrated that RVFV
NSs protein interacts with TFIIH p62, and subsequently
promotes its post-translational degradation [64]. The p62
protein was stabilized in the presence of proteasome inhibi-
tors, MG132 or lactacystin, and degradation occurred even
in the presence of a nuclear export inhibitor, leptomycin B,
or a lysosomal inhibitor, chloroquine. These studies demon-
strated that RVFV NSs protein induces host transcriptional
shutoff, by two potentially redundant mechanisms: (1)
interruption of TFIIH complex assembly by NSs-p44 bind-
ing, and (2) post-translational degradation of TFIIH p62
subunit.
Cellular protein degradation occurs mainly through the
ubiquitin (Ub)-proteasome system, where polyubiquitina-
tion of proteins with chains of at least four Lys 48-linked
Ubs leads to degradation through the 26S proteasome [65,
66]. To ubiquitinate proteins, three sequential steps are
necessary; (i) Ub-binding to E1 (the Ub activating enzyme),
(ii) transfer of Ub to E2 (the Ub conjugating enzyme) and
(iii) transfer of Ub from E2 to a substrate protein in the E3
ligase complex [66–68]. To promote the transfer of Ub to
TFIIH p62, it was hypothesized that RVFV NSs protein
serves as an adaptor protein in the E3 ligase complex [69].
The human cell encodes 8 different cullins (CUL1, 2, 3, 4A,
4B, 5, 7, and 9) [70]. As a scaffold protein, cullin bridges
either the Rbx1 or Rbx2 proteins, which encodes for the
RING domain. The ligase activity of the E3 ligase complex
is dependent on the covalent modification of cullin with
the ubiquitin-like modifier NEDD8 [71]. Different cullins
bind to their respective adaptor proteins; e.g., CUL1 or
CUL7 binds to Skp1 protein, CUL2 or CUL5 binds to elon-
gin BC complex, CUL3 binds to BTB-domain proteins, and
CUL4A binds to DNA-damage-binding protein-1 (DDB1)
[70]. Substrate receptor proteins bridge the E3 ligase with
specific substrate. For example, the CUL1-Skp1 or CUL7-
Skp1 complex binds to substrate receptors that encodes an
F-box motif, the CUL2-elongin BC or CUL5-elongin BC
complex binds to those encoding a suppressor of cytokine
signaling (SOCS) box motif, and the CUL3-BTB-domain
complex binds to their substrates via the C-terminus. Many
viral proteins bridges the cullin complex with their specific
substrate proteins: e.g., paramyxovirus V proteins, human
immunodeficiency virus Vif and Vpr proteins, adenovirus
E1b55K and E4orf6 proteins [67, 72–78]. Therefore, unique
specificity of virulence factors to substrate proteins may
contribute to the pathogenesis of viruses in animal hosts.
To characterize the mechanism of TFIIH p62 protein
degradation induced by RVFV NSs protein, proteomic
screening using recombinant RVFV encoding NSs with a
C-terminal TAP tag was accomplished. This resulted in
the identification of the F-box protein (FBXO3) as an
interacting partner protein for RVFV NSs protein [69].
Knockdown of FBXO3 or Skp1, inhibited p62 degradation
from RVFV NSs protein, however knockdown of Rbx,
CUL1 or CUL7 did not. The study also showed that the
interaction of RVFV NSs protein with CUL1 most likely
occurs through FBXO3 and Skp1 (Fig. 2). However, the
ubiquitination of p62 could not be demonstrated. The
FBXO3 (471 aa) has a full-length form (FBXO3/1) and a
C-terminus truncated short form (FBXO3/2: 415 aa).
Though FBXO3/1 is expressed in both the nucleus and
cytoplasm, the amount of FBXO3/1 proteins, but not
FBXO3/2 proteins, was shown to be decreased in cells in-
fected with RVFV. This in turn indicates the alteration of
protein turnover in FBXO3/1 proteins, which is due to its
incorporation into the E3 ligase complex.
Unlike RVFV NSs proteins, TOSV, SFTSV, or UUKV
NSs proteins localize in the cytoplasm only, and not the nu-
cleus [79–83]. The localization of other phlebovirus NSs is
currently unknown. The use of click chemistry, which cova-
lently links fluorescent dye to nascent RNA, allows for the
measurement of newly synthesized host RNA in infected
cells [84]. Cells that were infected with RVFV, showed de-
creased incorporation of 5-ethynyluridine (5-EU), a nucleo-
side analog, into newly synthesized nascent host mRNA.
Decreased 5-EU labeling also occurred in cells infected with
recombinant RVFV MP-12 strain (rMP-12) encoding PTV
NSs, in the place of MP-12 NSs [85]. However, this was not
the case with cells infected with rMP-12 encoding SFSV
NSs or TOSV NSs [85–87]. Though the mechanism has
yet to be defined, PTV NSs proteins may decrease host
transcriptional activities. Transcriptional regulations in-
duced by phlebovirus NSs proteins, other than RVFV NSs
protein, will need to be further characterized toward better
understanding of NSs proteins.
Bunyamwera virus (BUNV), which is a member of the
genus Orthobunyavirus (Bunyamwera serogroup), expresses
NSs proteins (101 amino acids) from the +1 ORF that over-
laps the N ORF. The NSs proteins of BUNV is also pre-
sented in both in the cytoplasm and nucleus [88]. The NSs
proteins of BUNV target cellular RNA polymerase II, by
inhibiting the phosphorylation of the C-terminal domain
(CTD), YSPTSPS repeats, of which various serine residues
are phosphorylated to regulate transcription [89]. Serine at
the 2nd or 5th position plays a role in mRNA elongation
and transcriptional initiation, respectively. BUNV NSs
protein inhibits CTD serine phosphorylation at the 2nd,
and not the 5th position, thus blocking the transition from
transcriptional initiation to mRNA elongation. BUNV NSs
protein also interacts with the mediator of RNA polymerase
II transcription subunit 8 (MED8) protein, which regulates
the transcriptional function of RNA polymerase II [90].
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Intriguingly, RNA polymerase II protein level was shown to
be decreased in BUNV infected cells, whereas this reduc-
tion did not occur when BUNV NSs protein lacked the
MED8-binding domain [90]. Léonard et al. proposed that
BUNV NSs protein mediates the degradation of RNA poly-
merase II through the E3 ligase complex, because the
MED8 is also incorporated into the Rbx1-CUL2-elongin
BC complex [90, 91]. However, the role of BUNV NSs
protein or MED8 in the putative E3 ligase complex in the
degradation of RNA polymerase II remains unknown. La
Crosse virus (LACV), which is a member of the California
serogroup of the genus Orthobunyavirus, also expresses
NSs protein (92 amino acids). The NSs protein of LACV
has a 38 % amino acid identity with BUNV NSs protein
[92]. Although LACV NSs protein does not bind to MED8,
it also induces the inhibition of cellular RNA polymerase II
CTD serine phosphorylation at the 2nd, and not at the 5th
position [93]. Furthermore, LACV NSs protein also in-
duces selective degradation of the hyperphosphorylated
IIO form of the RNA polymerase II RPB1 subunit via
the proteasome pathway. This in turn does not directly
have any effects with the hypophosphorylated IIA form
[93]. The degradation of RPB1 subunit occurs in cells
when the RNA polymerase II is stalled during elong-
ation [94]. However, it remains unknown whether
LACV NSs protein interacts with the E3 ligase complex
to specifically target RPB1 or not.
RVFV and TOSV NSs protein promotes
posttranslational degradation of dsRNA-dependent
protein kinase (PKR)
It is known that RVFV can replicate in the presence of host
transcriptional shutoff induced by actinomycin D (ActD)
[95]. To determine the role of RVFV NSs protein in the
presence of host transcriptional shutoff, viral replication
was characterized in cells treated with ActD. MP-12 repli-
cation was not decreased when infected Vero cells were
treated with ActD. However, recombinant MP-12 encoding
Renilla Luciferase (rLuc) in the place of NSs (rMP12-rLuc),
showed more than a 2 log reduction in viral titer when
infected Vero cells were treated with ActD [96]. This indi-
cated that RVFV NSs protein is capable of promoting viral
replication in the presence of host transcriptional shutoff.
Eukaryotic initiation factor (eIF) 2α was shown to be highly
phosphorylated in cells infected with rMP12-rLuc and
treated with ActD, whereas eIF2α phosphorylation was
minimal in cells infected with parental MP-12 and treated
with ActD [96].
Subsequently, it was also demonstrated that RVFV NSs
protein promotes the degradation of PKR [96, 97]. PKR
(551 amino acids; human) is a serine-threonine protein
kinase that is ubiquitously expressed in mammalian cells
[98–100]; the majority of PKR is found in the cytoplasm
and less than 20 % is found in the nucleus [100]. The deg-
radation of PKR in RVFV-infected cells occurred in both
Fig. 2 Schematics of RVFV NSs-mediated TFIIH suppression. The top portion of the figure illustrates that RVFV NSs protein binds to p44, and sequesters
it from the assembly site of TFIIH. Whereas the bottom portion of the figure illustrates the formation of the E3 ligase complex, consisting of cullin 1
(CUL1), Skp1, and FBXO3, and promoting the subsequent degradation of p62 through RVFV NSs
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the cytoplasm and nucleus [96]. Proteasomal inhibitors,
MG132 or lactacystin, stabilized PKR in the presence of
RVFV NSs protein. The accumulation of phosphorylated
eIF2α did not occur in ActD treated cells infected with
recombinant MP-12 encoding a dominant-negative PKR
(PKRΔE7). Since eIF2α phosphorylation leads to transla-
tion initiation shutoff, RVFV NSs protein serves a role in
facilitating efficient viral translation through blocking the
PKR-mediated eIF2α phosphorylation.
Using reverse genetics, a number of NSs point mutants
were subsequently screened for functional phenotypes.
Among those that were screened, the R173A mutant did
not promote PKR degradation, yet was able to still induce
transcriptional shutoff and inhibit IFN-β mRNA upregula-
tion [101]. Thus phosphorylation of eIF2α was induced in
cells infected with RVFV expressing NSs R173A mutant
without ActD treatment. Although the mechanism to in-
duce eIF2α phosphorylation by RVFV NSs R173A mutant
is unknown, the study showed that RVFV NSs mediated
transcription suppression and IFN-β gene suppression
occur independently from PKR degradation. The R173A
mutant did not interact with PKR, thus indicating the need
of the NSs-PKR interaction to trigger PKR degradation.
For NSs-mediated PKR degradation, the specific E3 ligase
complex has been further characterized [102, 103] (Fig. 3).
As described above, NEDD8 covalently binds to cullin
(NEDDylation), to recruit E2 to E3 ligase. Thus the NEDD8
activating enzyme (NAE1) is required for the NEDDylation.
As a small molecule inhibitor, MLN4924 functions as a
potent and selective inhibitor for NAE1 [104]. As a result, in
a dose-dependent manner, MLN4924 inhibited RVFV repli-
cation and increased the phosphorylation of PKR and eIF2α.
RVFV NSs protein was also screened for potential inter-
action with CUL 1, 2, 3, 4A, 4B, 5, 7, or 9. Of which, RVFV
NSs protein was found to only interact with CUL1. How-
ever, CUL1 mutants, ΔN53 or Y42A/M43A, which cannot
interact with Skp1, was shown to be poorly bound to NSs
protein. Therefore Skp1 mediates the interaction between
NSs protein and CUL1. To identify specific F-box protein,
which can interact with the CUL1-Skp1, 70 different F-box
genes were screened via siRNA assay. As a result, the
FBXW11 was screened out from siRNA pools from the re-
duction of RVFV replication [102] or PKR degradation
[103]. Since BTRC (also known as βTrCP1) and FBXW11
(also known as βTrCP2) are functional paralogs of the BTRC
gene (also known as βTrCP gene: Beta-transducin repeat
containing protein), further protein analysis was subse-
quently carried out for both. The siRNA knockdown of both
BTRC and FBXW11 mRNA inhibited RVFV replication
significantly more than the single knockdown of FBXW11
[102]. Similarly, siRNA knockdown of BTRC gene expres-
sion in FBXW11 knockout cells also completely abolished
PKR degradation by RVFV NSs protein [103]. The study
also demonstrated that the C-terminal WD40 domain
repeat of FBXW11 or BTRC, interacts with the C-terminal
of NSs protein, which contains the “degron” sequence
DDGFVE. Thus, RVFV NSs protein was identified as the
adaptor protein connecting the CUL1-Skp1-FBXW11 or the
CUL1-Skp1-BTRC complex with PKR. The ubiquitination
of PKR could not be demonstrated, however, this may be
due to low endogenous expression of PKR or high proteaso-
mal activity.
TOSV NSs (316 aa.), but not that of PTV or SFSV, was
also shown to promote the degradation of PKR similar to
Fig. 3 Schematics of RVFV NSs-mediated PKR degradation. RVFV NSs protein forms the E3 ligase complex, which consists of CUL1, Skp1, and
FBXW11. The E3 ligase complex promotes the degradation of PKR via the ubiquitin-proteasome pathway. NEDD8 activating enzyme (NAE1) can
be selectively inhibited by MLN4924
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that of RVFV [87]. Though RVFV and TOSV share similar
NSs functions, the amino acid sequence similarity is low,
with no shared motifs identified. To better understand the
potential mechanism commonly used in PKR degradation,
it is important to characterize the role of TOSV NSs pro-
tein in the putative E3 ligase complex. This may be ac-
complished through identifying PKR binding motifs, and
the type of cullin-RING complex used. It is also important
to recognize whether phleboviruses, other than RVFV and
TOSV, encode functions to facilitate viral translation with-
out affecting the PKR.
NSs proteins from RVFV, BUNV, and LACV localize in
both the nucleus and cytoplasm, and can induce a strong
shutoff of host protein synthesis in a NSs-dependent man-
ner [96, 105, 106]. Tick-borne UUKV or SFTSV expresses
cytoplasmic NSs and does not induce host translational
shutoff [107–109]. Although host translation is inhibited,
RVFV, BUNV, or LACV can maintain viral protein synthe-
sis during infection. Most bunyavirus mRNAs are unique,
because they lack the polyA tail at the 3′ terminus. The
polyadenylate binding protein 1 (PABP1) binds to the
polyA tail and the cap of mRNA via eIF4G, and mRNA
forms a circular structure for efficient translation [110].
RVFV NSs protein did not directly bind to PABP1, how-
ever, PABP1 was sequestered to nuclear speckles in cells
expressing RVFV NSs protein [111, 112]. Nuclear retention
of PABP also occurred in BUNV-infected cells at late stage
of infection, and it probably due to decreased host mRNA
in cytoplasm during NSs-mediated transcriptional shutoff
[113]. Thus, RVFV and BUNV NSs proteins facilitate
selective inhibition of host protein synthesis through tran-
scription shutoff. The knockdown of eIF4G, but not PABP,
decreased the translation of reporter gene flanked by
BUNV 5′-UTR and 3′-UTR, which lacks a polyA tail [113].
Hantaviruses, on the other hand, do not induce host trans-
lational shutoff and some do not even encode the NSs gene.
The N protein of hantaviruses functions as a surrogate for
the eIF4F complex (eIF4A, eIF4G, and eIF4F), and thus
recruits capped mRNA from the host to initiate viral trans-
lation [114]. Further study will be required to understand
bunyavirus NSs functions regulating host and viral protein
synthesis.
Suppression of interferon (IFN)-β gene up-
regulation by NSs protein of RVFV and other
bunyaviruses
Type-I, II, and III interferons (IFNs) play important roles
in the host defense against pathogens. IFNs exert their bio-
logical functions through the stimulation of target cells via
specific IFN receptors, using autocrine and paracrine sig-
naling processes. Through type-I IFN receptors (IFNAR),
Type-I IFNs stimulate various types of cells, including
lymphocytes, myeloid cells, epithelial cells, and stromal
cells. Type-III IFNs show limited target specificity, such as
epithelial cells, through type-III IFN receptor (IFNλR) [115–
117]. Type-II IFN is dominantly expressed from T cells and
NK cells, thus playing major roles in immunomodulation
and antiviral activities through lymphocytes [118]. Type-I
IFNs plays a major role in innate immunity during viral
infections. Cells stimulated through IFNAR induce various
IFN-stimulated genes (ISGs) to repress viral replication.
IFNB gene promoter activation is induced via the coordi-
nated binding of the homodimer of interferon regulatory
factor 3 (IRF3) (or the heterodimer of IRF3 and IRF7),
nuclear translocation of NFkB, and ATF2/cJun (AP1) to the
positive regulatory cis-elements for IFNB gene [119]. The
activation of these transcription factors are triggered by
the recognition of replicating viral RNA from pattern rec-
ognition receptors (PRRs), such as retinoic acid-inducible
gene I (RIG-I), melanoma differentiation-associated gene
5 (MDA5), or endosomal viral RNA through Toll-like re-
ceptors (TLRs) [115, 119]. Binding of viral RNA to RIG-I
or MDA5 leads to their interaction with mitochondrial
antiviral signaling protein (MAVS), and activation of
TBK1 [tumor necrosis-receptor associated factor (TRAF)
family member associated NFkB activator-binding kinase
1] [119]. Activated TBK1 induces phosphorylation and
dimerization of IRF3 and IRF7.
RVFV NSs protein is a type-I IFN antagonist, and thus
supports efficient viral replication in type-I IFN-competent
cells or immune-competent hosts [120, 121]. A natural
isolate, RVFV Clone 13 strain (C13), encodes an in-frame
truncation of the NSs ORF from aa.16 to 198 (69 % of NSs
ORF). The IFN-β mRNA can be upregulated as early as 3–
6 h post infection with the C13 strain [60]. Bouloy et al.
analyzed the virulence of reassortant RVFV generated
between C13 and ZH548 strains in inbred 129/SvPaslco
mice. They confirmed the attenuation of RVFV encoding
C13 S-segment, and the rapid induction of type-I IFNs in
the absence of intact NSs [121]. Therefore, the NSs is
considered to be the major virulence factor for RVFV.
Cells infected with RVFV strain encoding intact NSs pro-
tein did not upregulate IFN-β mRNA, but still activated
RIG-I, dimerization and nuclear translocation of IRF3, and
nuclear translocation of NFkB and AP1 [60, 122]. Thus,
RVFV NSs protein inhibits the upregulation of IFN-β
promoter downstream of the activation of transcription
factors. Le May et al. [123] demonstrated that NSs protein
binds to Sin3A Associated Protein 30 (SAP30) and subse-
quently prevents the activation of IFN-β promoter via
interaction with a transcription factor, Yin Yang 1 (YY1)
protein in mouse cells [124]. In the presence of NSs-
SAP30-YY1 complex, the CREB-binding protein was not
recruited to the IFN-β promoter, and subsequent acetyl-
ation of histone K8H4 or K14H3 did not occur. The RVFV
NSs protein aa.210-230 was mapped to bind to SAP30
protein, and replication of recombinant RVFV encoding
NSsΔ210-230 induced IFN-β mRNA in infected cells. In
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addition, the NSsΔ210-230 protein did not form NSs fila-
ment, or interact with SAP30 or IFN-β promoter. Thus,
this study indicated that IFN-β promoter activation is
inhibited from the interaction between RVFV NSs protein
and SAP30 protein.
On the other hand, 11 different RVFV NSs mutants,
encoding serial in-frame 25 aa truncation, did not suppress
IFN-β gene upregulation, regardless of the location of
truncations [125]. This indicated that RVFV NSs mutants
failed to exert biological functions due to structural
changes or alteration of subcellular localizations. Another
study demonstrated that the TFIIH inhibition may also be
responsible for the IFN-β promoter suppression. The
siRNA knockdown of FBXO3 mRNA (E3 ligase for p62)
allowed induction of IFN-β mRNA during RVFV infection
[69]. The gaps in biological phenotypes should be further
investigated for a better understanding of the mechanism.
TOSV NSs protein localizes to the cytoplasm, and in-
hibits nuclear localization of IRF3 [79]. In addition, TOSV
NSs protein interacted with the N-terminal CARD domain
of RIG-I, and promoted the degradation of RIG-I via the
proteasome [126]. The inhibition of IFN-β clearly occurred
when TOSV NSs was expressed from plasmid DNA or
recombinant RVFV, however, it was weak in cells infected
with authentic TOSV. This may most likely be due to the
low expression level of NSs [79, 86, 126]. Later on, it was
suggested that TOSV isolates from the Spanish lineage
inhibits IFN-β gene more efficiently than those from the
Italian lineage [127].
SFSV NSs protein inhibits the induction of IFN-β gene,
however, the inhibition mechanism of type-I IFN suppres-
sion remains unknown [85, 97]. In addition, SFSV NSs
protein induces neither host general transcription shutoff,
nor PKR degradation [85, 97]. However, cells transfected
with a reporter plasmid expressing Renilla luciferase
under constitutively active SV40 promoter, showed an
increase in reporter activity when SFSV NSs proteins were
co-expressed [85]. Thus, SFSV NSs protein probably en-
codes a biological function upregulating host gene expres-
sion either via transcriptional or translational level, with
unknown mechanism.
PTV NSs protein also inhibits IFN-β gene induction. The
PTV Adames strain is highly pathogenic in hamsters and
mice, whereas the PTV Balliet strain does not [128–130].
Similar to TOSV infection, authentic PTV did not com-
pletely inhibit the induction of IFN-β in infected cells. When
infected with the PTV Balliet strain, type-I IFN was induced
more abundantly in hamster embryonic fibroblast cells or
mouse primary macrophages than with the Adames strain
[130, 131]. In addition, PTV NSs protein expressed from
plasmids or recombinant RVFV exerted a more efficient
biological function than that expressed from PTV. In a
reporter assay, PTV Balliet strain NSs protein inhibited Sen-
dai virus-mediated IFN-β promoter activation less efficiently
than PTV Adames strain NSs protein (~4-fold) [130]. Re-
combinant RVFV MP-12 strain encoding PTV Adames
strain NSs was able to completely inhibit the up-regulation
of mouse IFN-β mRNA and ISG56 mRNA [85]. It remains
unknown how PTV NSs protein targets type-I IFN induc-
tion pathway, or how the replications of PTV Adames and
PTV Balliet strains differentially induce type-I IFNs in the
presence of NSs protein.
Tick-borne SFTSV NSs protein forms cytoplasmic inclu-
sion bodies, binds to IRF3 via TBK1 (or IKKε) and then
relocates them to cytoplasmic inclusion bodies. This in turn
inhibits the induction of IFN-β gene, since IRF3 is being
sequestered to cytoplasmic inclusion bodies [82, 83, 132].
In inclusion bodies, the SFTSV NSs-TBK1 complex was
also associated with RIG-I and the E3 ligase TRIM25 [83].
Interestingly, SFTSV NSs inclusion bodies sequestered the
cellular signal transducer and activator of transcription 2
(STAT2) and relocated both STAT1 and STAT2 to cyto-
plasmic inclusion bodies [133]. Thus, SFTSV NSs inclusion
bodies play a key role in the inhibition of type-I IFN induc-
tion and signaling pathways. Other studies also indicated
that SFTSV NSs protein forms viroplasm-like structure,
containing NSs, N, dsRNA, and lipid droplets, suggesting
the role of SFTSV NSs as a scaffold protein for viral RNA
replication [81].
BUNV NSs protein inhibits IFN-β gene upregulation
[105, 134] but does not inhibit the homodimerization or
nuclear translocation of IRF3 [135]. Thus, the suppression
of IFN-β promoter by BUNV NSs occurs downstream of
the IRF3 activation. BUNV NSs protein may also inhibit
IFN-β gene upregulation directly via blocking mRNA
elongation of host RNA polymerase II [89].
Similarly to the IFN-β promoter suppression mechanism
through SAP30-NSs binding, RVFV NSs protein also alters
the process of mitosis in infected cells. RVFV-infected cells
showed abnormal nuclei, such as lobulated nuclei, intranuc-
lear DNA bridge, or micronuclei, in an NSs-dependent
manner [136]. Through the SAP30-binding domain (amino
acid 210–230), RVFV NSs filament interacted with pericen-
tromeric major γ-satellite sequence, but not centromeric
minor α-satellite sequence. It was also indicated that YY1
may mediate the interaction between the NSs-SAP30 com-
plex and the γ-satellite sequence DNA. Since RVFV NSs
protein accumulates in the nucleus, host cells also induce
DNA damage signaling, including ataxia-telangiectasia mu-
tated (ATM), checkpoint kinase 2 (Chk.2), and p53 [137].
RVFV NSs protein also triggers cell cycle arrests, either at
the S phase (MP-12 strain) or the G0/G1 phase (ZH548
strain) [137]. Abnormal replication of infected cells, through
NSs-mediated DNA damages, affects normal tissue differen-
tiation, and may play a part in the pathogenesis of fetal mal-
formation in infected ruminants.
Although RVFV NSs proteins shutoff host general tran-
scription, including IFN-β gene, the host immune response
Ly and Ikegami Virology Journal  (2016) 13:118 Page 8 of 13
to RVFV infected cells in vivo is unpredictable. Cytokine
profiles were analyzed from human sera: six fatal and 20
non-fatal cases in Saudi Arabia [138], or 19 fatal and 85
non-fatal cases in South Africa [139]. Fatal cases showed
elevated IL-10 (suppression of cell-mediated immune
responses), IL-1RA (antagonist for IL-1), IP-10, MCP-1,
CXCL9, or IL-8, indicating that fatal cases of RVF failed to
mount a systemic pro-inflammatory cytokine response.
Mitochondrial antiviral signaling (Mavs) gene knockout
mice are a highly lethal RVFV infection model using MP-
12 strain, and MCP-1, IL-10, IL-6, and CXCL9 were also
significantly increased during RVFV infection [122]. The
transcriptional profile of RVFV infected mouse cells was
characterized at a relatively early stage of infection (8 hpi)
using Chromatin immunoprecipitation (ChIP) and a mouse
promoter array [140]. RVFV ZH548 strain showed signifi-
cant downregulation of ten genes, including Fbox3, Map-
k8ip3, Stat2, IL3, IL10rb, Tyk2, Casp9, Phf21, Ncoa3, and
Notch4, when compared to recombinant ZH548 lacking
NSs (ZHΔNSs). This indicated the impact of NSs expres-
sion on apoptosis, innate immunity, and other immuno-
logical pathways. Accordingly, cytokine profiles can be
important markers to predict the severity of RVFV infec-
tion, and will thus be useful to evaluate the effect of anti-
viral treatments.
Conclusion
Genetically, bunyaviruses are highly diverse, and some
species can cause lethal infections in humans or live-
stock. RVFV is one of the most important bunyaviruses,
and has caused large outbreaks in both ruminants and
humans, resulting in devastating economic loss in af-
fected regions. The major virulence factor NSs, exerts
several different biological functions to hijack infected
cells. Each mechanism is apparently similar to those
used by other bunyavirus NSs proteins, as summarized
in Table 1. The degradation of PKR is induced by RVFV
and TOSV NSs proteins. RVFV NSs protein also pro-
motes the degradation of TFIIH p62 protein, whereas
TOSV NSs protein triggers the degradation of RIG-I.
Since RVFV NSs protein functions as viral adaptor pro-
tein to form the E3 ligase complex for p62 or PKR deg-
radation, similar mechanisms may be utilized by TOSV
NSs protein for PKR or RIG-I degradation. Host general
transcription suppression is induced by RVFV, BUNV,
and LACV NSs proteins. These NSs proteins induce
DNA damage responses, and trigger host translational
shutoff. The expression of IFN-β gene is suppressed at
the transcriptional level, which is in sharp contrast with
other NSs proteins, as they only localize in the cyto-
plasm (e.g., TOSV, SFTSV). TOSV or SFTSV NSs pro-
teins inhibit specific proteins in the IFN-β gene
induction pathway (e.g., RIG-I, TBK-1). Further grouping
of phleboviruses and orthobunyaviruses based on NSs
protein functions will lead to effective strategies geared
towards combating pathogenic bunyaviruses. Many
bunyaviruses are neglected from funding agencies or
public health policies, due to restricted viral distribu-
tions in specific arthropod vectors (e.g., sandfly, ticks),
as well as limited marketability of vaccines or antivirals.
Thus, further understanding of the unique biological
function of the NSs protein in viruses that are currently
uncharacterized, will be important in uncovering viral
strategies used to adapt to both arthropod insects and
vertebrates.
Abbreviations
ActD, actinomycin D; AP1, activating transcription factor 2/cJun; APOBEC3G,
the apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G; ATM,
ataxia-telangiectasia mutated; ATR, ataxia-telangiectasia mutated and Rad3-related
kinase; BC, elongin BC; BTB, broad-complex, tramtrack and bric a brac; BTRC,



















[96, 97, 102, 103]
Sequestration of PABP1
[111, 112]






Degradation of PKR [87]
SFTSV C Suppression of IFN-β
gene activation
Sequestration of TBK1/









BUNV N, C Host general
transcription
suppression









LACV N, C Host general
transcription
suppression









N nucleus, C cytoplasm
Ly and Ikegami Virology Journal  (2016) 13:118 Page 9 of 13
beta-transducin repeat containing E3 ubiquitin protein kinase; BUNV, bunyamwera
virus; Cdk7, cyclin-dependent kinase 7; ChIP, chromatin immunoprecipitation;
Chk.2, checkpoint kinase 2; CTD, C-terminal domain; CUL, cullin; CXCL9, chemokine
(C-X-C motif) ligand 9; dsRBMs, dsRNA-binding motifs; eIF2α, eukaryotic initiation
factor 2α; eIF4F, eukaryotic initiation factor 4 F; eIF4G, eukaryotic initiation factor
4G; FRIV, Frijoles virus; HIV, human immunodeficiency virus; ICOV, Icoaraci virus;
IFN, interferon; IFNAR, interferon-α/β receptor; IRF3, interferon regulatory factor 3;
IRF7, interferon regulatory factor 7; ISGs, IFN-stimulated genes; LACV, La Crosse
virus; L-segment, large-segment; MAT1, menage a trois 1; MAVS, mitochondrial
antiviral signaling; MCP-1, monocyte chemoattractant protein-1; MDA5, melanoma
differentiation-associated gene 5; M-segment, medium-segment; NAE1, NEDD8
activating enzyme 1; NEDD8, neural precursor cell expressed developmentally
downregulated protein 8; NIAID, National Institute of Allergy and Infectious
Diseases; NIH, National Institutes of Health; NS, nonstructural protein; NSs,
nonstructural protein on the S segment; ORF, open reading frame; PABP1,
polyadenylate binding protein 1; PKR, dsRNA-dependent protein kinase; PRRs,
pattern recognition receptors; PTV, Punta Toro virus; RIG-I, retinoic acid-inducible
gene 1; RING, really interesting new gene; rLuc, Renilla luciferase; RVF, Rift Valley
fever; RVFV, Rift Valley fever virus; SAP30, Sin3A-associated 30-kD protein; SFSV,
sandfly fever sicilian virus; SFTS, severe fever with thrombocytopenia syndrome;
SFTSV, severe fever with thrombocytopenia syndrome virus; Skp1, S-phase
kinase-associated protein 1; SOCS, suppressor of cytokine signaling; S-segment,
small-segment; STATs, signal transducers and activators of transcription; TBP,
TATA-binding protein; TFIIH, transcription factor IIH; TLRs, toll-like receptors;
TOSV, toscana virus; TRAF, tumor necrosis-receptor associated factor; Ub,
ubiquitin; UUKV, uukuniemi virus; XPB, xeroderma pigmentosum type B; XPD,
xeroderma pigmentosum group D; YY1, Yin Yang 1; βTrCP, Beta-transducin
repeat containing protein
Acknowledgments
We thank for educational and research supports through the Sealy Center for
Vaccine Development at The University of Texas Medical Branch at Galveston
(UTMB). This review was partly supported by the National Institute of Health
(grant number R01 AI087643-01A1).
Funding
This work was partly supported by the National Institute of Health (grant
number R01 AI087643-01A1) (T.I.), and the funding from the Sealy Center for
Vaccine Development at The University of Texas Medical Branch at Galveston
(UTMB) (TI).
Availability of data and materials
Not applicable.
Authors’ contributions
HJL and TI drafted the manuscript and designed artworks. Both authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Pathology, The University of Texas Medical Branch at
Galveston, Galveston, TX, USA. 2The Sealy Center for Vaccine Development,
The University of Texas Medical Branch at Galveston, Galveston, TX, USA.
3The Center for Biodefense and Emerging Infectious Diseases, The University
of Texas Medical Branch at Galveston, Galveston, TX, USA.
Received: 25 May 2016 Accepted: 23 June 2016
References
1. Daubney R, Hudson JR. Enzootic hepatitis or Rift Valley fever: An
undescribed virus disease of sheep cattle and man from east Africa. J Pathol
Bacteriol. 1931;34:545–79.
2. Swanepoel R, Coetzer JAW. Rift Valley fever. In: Coetzer JAW, Tustin RC,
editors. Infectious diseases of livestock with special reference to southern
Africa. 2nd ed. Cape Town: Oxford University Press; 2004. p. 1037–70.
3. Shoemaker T, Boulianne C, Vincent MJ, Pezzanite L, Al-Qahtani MM,
Al-Mazrou Y, et al. Genetic analysis of viruses associated with emergence of
Rift Valley fever in Saudi Arabia and Yemen, 2000–01. Emerg Infect Dis.
2002;8:1415–20.
4. Carroll SA, Reynes JM, Khristova ML, Andriamandimby SF, Rollin PE, Nichol
ST. Genetic evidence for Rift Valley fever outbreaks in Madagascar resulting
from virus introductions from the East African mainland rather than
enzootic maintenance. J Virol. 2011;85:6162–7.
5. Meegan JM. The Rift Valley fever epizootic in Egypt 1977–78. 1. Description of the
epizzotic and virological studies. Trans R Soc Trop Med Hyg. 1979;73:618–23.
6. Bird BH, Khristova ML, Rollin PE, Ksiazek TG, Nichol ST. Complete
genome analysis of 33 ecologically and biologically diverse Rift Valley
fever virus strains reveals widespread virus movement and low genetic
diversity due to recent common ancestry. J Virol. 2007;81:2805–16.
7. Schmaljohn C, Nichol ST. Bunyaviridae. In: Knipe DM, Howley PM, Griffin
DE, Lamb RA, Martin MA, Roizman B, Straus SE, editors. Fields Virology.
5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2007. p. 1741–89.
8. Coetzer JA, Barnard BJ. Hydrops amnii in sheep associated with
hydranencephaly and arthrogryposis with wesselsbron disease and rift valley
fever viruses as aetiological agents. Onderstepoort J Vet Res. 1977;44:119–26.
9. Easterday BC. Rift valley fever. Adv Vet Sci. 1965;10:65–127.
10. Ikegami T, Makino S. The Pathogenesis of Rift Valley Fever. Viruses. 2011;3:493–519.
11. CDC. Rift Valley fever outbreak–Kenya, November 2006-January 2007.
MMWR Morb Mortal Wkly Rep. 2007;56:73–6.
12. Bird BH, Ksiazek TG, Nichol ST, Maclachlan NJ. Rift Valley fever virus. J Am
Vet Med Assoc. 2009;234:883–93.
13. Linthicum KJ, Davies FG, Kairo A, Bailey CL. Rift Valley fever virus (family
Bunyaviridae, genus Phlebovirus). Isolations from Diptera collected during
an inter-epizootic period in Kenya. J Hyg (Lond). 1985;95:197–209.
14. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus
(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular
epidemiology, vectors, diagnostics and prevention. Vet Res. 2010;41:61.
15. Turell MJ, Dohm DJ, Fonseca DM. Comparison of the Potential for Different
Genetic Forms in the Culex pipiens Complex in North America to Transmit
Rift Valley Fever Virus. J Am Mosq Control Assoc. 2014;30:253–9.
16. Balenghien T, Cardinale E, Chevalier V, Elissa N, Failloux AB, Jean Jose
Nipomichene TN, et al. Towards a better understanding of Rift Valley fever
epidemiology in the south-west of the Indian Ocean. Vet Res. 2013;44:78.
17. CDC. Rift Valley fever with retinopathy-Canada. MMWR Morb Mortal Wkly
Rep. 1979;28:607–8.
18. Mansfield KL, Banyard AC, McElhinney L, Johnson N, Horton DL, Hernandez-
Triana LM, et al. Rift Valley fever virus: A review of diagnosis and vaccination,
and implications for emergence in Europe. Vaccine. 2015;33:5520–31.
19. Miller MM, Bennett KE, Drolet BS, Lindsay R, Mecham JO, Reeves WK, et al.
Evaluation of the efficacy, potential for vector transmission, and duration of
immunity of MP-12, an attenuated Rift Valley fever virus vaccine candidate,
in sheep. Clin Vaccine Immunol. 2015;22:930–7.
20. Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL. Prophylaxis of Rift
Valley fever with antiviral drugs, immune serum, an interferon inducer, and
a macrophage activator. Antiviral Res. 1986;6:285–97.
21. Kende M, Alving CR, Rill WL, Swartz Jr GM, Canonico PG. Enhanced efficacy
of liposome-encapsulated ribavirin against Rift Valley fever virus infection in
mice. Antimicrob Agents Chemother. 1985;27:903–7.
22. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin,
a broad-spectrum antiviral drug. Rev Infect Dis. 1989;11 Suppl 4:S750–61.
23. Kende M, Lupton HW, Rill WL, Levy HB, Canonico PG. Enhanced therapeutic
efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever
virus infection in mice. Antimicrob Agents Chemother. 1987;31:986–90.
24. Kende M. Prophylactic and therapeutic efficacy of poly(I, C)-LC against Rift
Valley fever virus infection in mice. J Biol Response Mod. 1985;4:503–11.
25. Morrill JC, Jennings GB, Cosgriff TM, Gibbs PH, Peters CJ. Prevention of Rift
Valley fever in rhesus monkeys with interferon-alpha. Rev Infect Dis. 1989;11
Suppl 4:S815–25.
26. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy,
side effects, and complications. Gut. 2006;55:1350–9.
27. Elliott RM. Orthobunyaviruses: recent genetic and structural insights. Nat
Rev Microbiol. 2014;12:673–85.
28. Jaaskelainen KM, Kaukinen P, Minskaya ES, Plyusnina A, Vapalahti O, Elliott
RM, et al. Tula and Puumala hantavirus NSs ORFs are functional and the
products inhibit activation of the interferon-beta promoter. J Med Virol.
2007;79:1527–36.
Ly and Ikegami Virology Journal  (2016) 13:118 Page 10 of 13
29. Altamura LA, Bertolotti-Ciarlet A, Teigler J, Paragas J, Schmaljohn CS, Doms
RW. Identification of a novel C-terminal cleavage of Crimean-Congo
hemorrhagic fever virus PreGN that leads to generation of an NSM protein.
J Virol. 2007;81:6632–42.
30. Kormelink R, Storms M, Van Lent J, Peters D, Goldbach R. Expression and
subcellular location of the NSM protein of tomato spotted wilt virus (TSWV),
a putative viral movement protein. Virology. 1994;200:56–65.
31. Barnwal B, Karlberg H, Mirazimi A, Tan YJ. The Non-structural Protein of
Crimean-Congo Hemorrhagic Fever Virus Disrupts the Mitochondrial
Membrane Potential and Induces Apoptosis. J Biol Chem. 2016;291:582–92.
32. Reguera J, Weber F, Cusack S. Bunyaviridae RNA polymerases (L-protein)
have an N-terminal, influenza-like endonuclease domain, essential for viral
cap-dependent transcription. PLoS Pathog. 2010;6:e1001101.
33. Garcin D, Lezzi M, Dobbs M, Elliott RM, Schmaljohn C, Kang CY, et al. The 5'
ends of Hantaan virus (Bunyaviridae) RNAs suggest a prime-and-realign
mechanism for the initiation of RNA synthesis. J Virol. 1995;69:5754–62.
34. Klemm C, Reguera J, Cusack S, Zielecki F, Kochs G, Weber F. Systems to
establish bunyavirus genome replication in the absence of transcription.
J Virol. 2013;87:8205–12.
35. Morin B, Coutard B, Lelke M, Ferron F, Kerber R, Jamal S, et al. The N-terminal
domain of the arenavirus L protein is an RNA endonuclease essential in mRNA
transcription. PLoS Pathog. 2010;6:e1001038.
36. Ikegami T, Won S, Peters CJ, Makino S. Characterization of Rift Valley fever
virus transcriptional terminations. J Virol. 2007;81:8421–38.
37. Albarino CG, Bird BH, Nichol ST. A shared transcription termination signal on
negative and ambisense RNA genome segments of Rift Valley fever, sandfly
fever Sicilian, and Toscana viruses. J Virol. 2007;81:5246–56.
38. Lara E, Billecocq A, Leger P, Bouloy M. Characterization of wild-type and
alternate transcription termination signals in the Rift Valley fever virus
genome. J Virol. 2011;85:12134–45.
39. Barr JN. Bunyavirus mRNA synthesis is coupled to translation to prevent
premature transcription termination. RNA. 2007;13:731–6.
40. Barr JN, Rodgers JW, Wertz GW. Identification of the Bunyamwera
bunyavirus transcription termination signal. J Gen Virol. 2006;87:189–98.
41. Gerrard SR, Nichol ST. Synthesis, proteolytic processing and complex
formation of N-terminally nested precursor proteins of the Rift Valley fever
virus glycoproteins. Virology. 2007;357:124–33.
42. Weingartl HM, Zhang S, Marszal P, McGreevy A, Burton L, Wilson WC. Rift
Valley fever virus incorporates the 78 kDa glycoprotein into virions matured
in mosquito C6/36 cells. PLoS ONE. 2014;9:e87385.
43. Kreher F, Tamietti C, Gommet C, Guillemot L, Ermonval M, Failloux AB, et al.
The Rift Valley fever accessory proteins NSm and P78/NSm-Gn are
determinants of virus propagation in vertebrate and invertebrate hosts.
Emerg Microbes Infect. 2014;3:e71.
44. Kading RC, Crabtree MB, Bird BH, Nichol ST, Erickson BR, Horiuchi K, et al.
Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus
replication in and dissemination from the midgut of Aedes aegypti
mosquitoes. PLoS Negl Trop Dis. 2014;8:e2670.
45. Crabtree MB, Kent Crockett RJ, Bird BH, Nichol ST, Erickson BR, Biggerstaff BJ,
et al. Infection and transmission of Rift Valley fever viruses lacking the NSs and/
or NSm genes in mosquitoes: potential role for NSm in mosquito infection.
PLoS Negl Trop Dis. 2012;6:e1639.
46. Won S, Ikegami T, Peters CJ, Makino S. NSm protein of Rift Valley fever virus
suppresses virus-induced apoptosis. J Virol. 2007;81:13335–45.
47. Terasaki K, Won S, Makino S. The C-terminal region of Rift Valley fever virus
NSm protein targets the protein to the mitochondrial outer membrane and
exerts anti-apoptotic function. J Virol. 2013;87:676–82.
48. Plyusnina A, Beaty BJ, Elliott RM, Goldbach R, Kormelink R, Lundkvist A, et al.
Family Bunyaviridae. In: King AMQ, Adams MJ, Carsten EB, Lefkowitz EJ,
editors. Virus taxonomy: ninth report of the International Committee on
Taxonomy of Viruses. 1st ed. London: Elsevier; 2011. p. 725–41.
49. Dionisio D, Esperti F, Vivarelli A, Valassina M. Epidemiological, clinical and
laboratory aspects of sandfly fever. Curr Opin Infect Dis. 2003;16:383–8.
50. Sabin AB. Experimental studies on Phlebotomus (pappataci, sandfly) fever
during World War II. Arch Gesamte Virusforsch. 1951;4:367–410.
51. Tesh RB. The genus Phlebovirus and its vectors. Annu Rev Entomol. 1988;33:169–81.
52. Liu S, Chai C, Wang C, Amer S, Lv H, He H, et al. Systematic review of severe
fever with thrombocytopenia syndrome: virology, epidemiology, and clinical
characteristics. Rev Med Virol. 2014;24:90–102.
53. Liu Q, He B, Huang SY, Wei F, Zhu XQ. Severe fever with thrombocytopenia
syndrome, an emerging tick-borne zoonosis. Lancet Infect Dis. 2014;14:763–72.
54. Saito T, Fukushima K, Umeki K, Nakajima K. Severe fever with
thrombocytopenia syndrome in Japan and public health communication.
Emerg Infect Dis. 2015;21:487–9.
55. Yun SM, Lee WG, Ryou J, Yang SC, Park SW, Roh JY, et al. Severe fever with
thrombocytopenia syndrome virus in ticks collected from humans, South
Korea, 2013. Emerg Infect Dis. 2014;20:1358–61.
56. Vasconcelos PF, Calisher CH. Emergence of Human Arboviral Diseases in the
Americas, 2000–2016. Vector Borne Zoonotic Dis. 2016;16:295–301.
57. Xu F, Chen H, Travassos da Rosa AP, Tesh RB, Xiao SY. Phylogenetic
relationships among sandfly fever group viruses (Phlebovirus: Bunyaviridae)
based on the small genome segment. J Gen Virol. 2007;88:2312–9.
58. Giorgi C, Accardi L, Nicoletti L, Gro MC, Takehara K, Hilditch C, et al. Sequences
and coding strategies of the S RNAs of Toscana and Rift Valley fever viruses
compared to those of Punta Toro, Sicilian Sandfly fever, and Uukuniemi viruses.
Virology. 1991;180:738–53.
59. Yadani FZ, Kohl A, Prehaud C, Billecocq A, Bouloy M. The carboxy-terminal
acidic domain of Rift Valley Fever virus NSs protein is essential for the
formation of filamentous structures but not for the nuclear localization of
the protein. J Virol. 1999;73:5018–25.
60. Billecocq A, Spiegel M, Vialat P, Kohl A, Weber F, Bouloy M, et al. NSs
protein of Rift Valley fever virus blocks interferon production by inhibiting
host gene transcription. J Virol. 2004;78:9798–806.
61. Cyr N, de la Fuente C, Lecoq L, Guendel I, Chabot PR, Kehn-Hall K, et al.
A OmegaXaV motif in the Rift Valley fever virus NSs protein is essential for
degrading p62, forming nuclear filaments and virulence. Proc Natl Acad Sci
U S A. 2015;112:6021–6.
62. Le May N, Dubaele S, Proietti De Santis L, Billecocq A, Bouloy M, Egly JM.
TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus.
Cell. 2004;116:541–50.
63. Iben S, Tschochner H, Bier M, Hoogstraten D, Hozak P, Egly JM, et al. TFIIH plays
an essential role in RNA polymerase I transcription. Cell. 2002;109:297–306.
64. Kalveram B, Lihoradova O, Ikegami T. NSs Protein of Rift Valley Fever Virus
Promotes Post-Translational Downregulation of the TFIIH Subunit p62.
J Virol. 2011;85:6234–43.
65. Sorokin AV, Kim ER, Ovchinnikov LP. Proteasome system of protein
degradation and processing. Biochemistry (Mosc). 2009;74:1411–42.
66. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–79.
67. Randow F, Lehner PJ. Viral avoidance and exploitation of the ubiquitin
system. Nat Cell Biol. 2009;11:527–34.
68. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem. 2012;81:203–29.
69. Kainulainen M, Habjan M, Hubel P, Busch L, Lau S, Colinge J, et al. Virulence
factor NSs of rift valley fever virus recruits the F-box protein FBXO3 to degrade
subunit p62 of general transcription factor TFIIH. J Virol. 2014;88:3464–73.
70. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin
ligases. Nat Rev Mol Cell Biol. 2005;6:9–20.
71. Deshaies RJ, Joazeiro CA. RING domain E3 ubiquitin ligases. Annu Rev
Biochem. 2009;78:399–434.
72. Chen M, Gerlier D. Viral hijacking of cellular ubiquitination pathways as an
anti-innate immunity strategy. Viral Immunol. 2006;19:349–62.
73. Li T, Chen X, Garbutt KC, Zhou P, Zheng N. Structure of DDB1 in complex
with a paramyxovirus V protein: viral hijack of a propeller cluster in ubiquitin
ligase. Cell. 2006;124:105–17.
74. Wolfe LS, Stanley BJ, Liu C, Eliason WK, Xiong Y. Dissection of the HIV Vif
interaction with human E3 ubiquitin ligase. J Virol. 2010;84:7135–9.
75. Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR. Human immunodeficiency
virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA
glycosylases. J Virol. 2005;79:10978–87.
76. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA. HIV-1 Vpr-
mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase.
PLoS Pathog. 2007;3:e85.
77. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, et al.
HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the
Cul4-DDB1 ubiquitin ligase. Cell Cycle. 2007;6:182–8.
78. Dallaire F, Blanchette P, Groitl P, Dobner T, Branton PE. Identification of integrin
alpha3 as a new substrate of the adenovirus E4orf6/E1B 55-kilodalton E3
ubiquitin ligase complex. J Virol. 2009;83:5329–38.
79. Gori Savellini G, Weber F, Terrosi C, Habjan M, Martorelli B, Cusi MG. Toscana
virus induces interferon although its NSs protein reveals antagonistic
activity. J Gen Virol. 2011;92:71–9.
80. Simons JF, Persson R, Pettersson RF. Association of the nonstructural protein NSs
of Uukuniemi virus with the 40S ribosomal subunit. J Virol. 1992;66:4233–41.
Ly and Ikegami Virology Journal  (2016) 13:118 Page 11 of 13
81. Wu X, Qi X, Liang M, Li C, Cardona CJ, Li D, et al. Roles of viroplasm-like
structures formed by nonstructural protein NSs in infection with severe
fever with thrombocytopenia syndrome virus. FASEB J. 2014;28:2504–16.
82. Wu X, Qi X, Qu B, Zhang Z, Liang M, Li C, et al. Evasion of antiviral immunity
through sequestering of TBK1/IKKepsilon/IRF3 into viral inclusion bodies.
J Virol. 2014;88:3067–76.
83. Santiago FW, Covaleda LM, Sanchez-Aparicio MT, Silvas JA, Diaz-Vizarreta
AC, Patel JR, et al. Hijacking of RIG-I signaling proteins into virus-induced
cytoplasmic structures correlates with the inhibition of type I interferon
responses. J Virol. 2014;88:4572–85.
84. Kalveram B, Lihoradova O, Indran SV, Head JA, Ikegami T. Using click
chemistry to measure the effect of viral infection on host-cell RNA synthesis.
J Vis Exp. 2013;78:50809.
85. Lihoradova OA, Indran SV, Kalveram B, Lokugamage N, Head JA, Gong B, et al.
Characterization of Rift Valley Fever Virus MP-12 Strain Encoding NSs of Punta
Toro Virus or Sandfly Fever Sicilian Virus. PLoS Negl Trop Dis. 2013;7:e2181.
86. Indran SV, Lihoradova OA, Phoenix I, Lokugamage N, Kalveram B, Head JA,
et al. Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs
retains neuroinvasiveness in mice. J Gen Virol. 2013;94:1441–50.
87. Kalveram B, Ikegami T. Toscana Virus NSs Protein Promotes Degradation of
Double-Stranded RNA-Dependent Protein Kinase. J Virol. 2013;87:3710–8.
88. Weber F, Dunn EF, Bridgen A, Elliott RM. The Bunyamwera virus
nonstructural protein NSs inhibits viral RNA synthesis in a minireplicon
system. Virology. 2001;281:67–74.
89. Thomas D, Blakqori G, Wagner V, Banholzer M, Kessler N, Elliott RM, et al.
Inhibition of RNA polymerase II phosphorylation by a viral interferon
antagonist. J Biol Chem. 2004;279:31471–7.
90. Leonard VH, Kohl A, Hart TJ, Elliott RM. Interaction of Bunyamwera
Orthobunyavirus NSs protein with mediator protein MED8: a mechanism for
inhibiting the interferon response. J Virol. 2006;80:9667–75.
91. Brower CS, Sato S, Tomomori-Sato C, Kamura T, Pause A, Stearman R, et al.
Mammalian mediator subunit mMED8 is an Elongin BC-interacting protein
that can assemble with Cul2 and Rbx1 to reconstitute a ubiquitin ligase.
Proc Natl Acad Sci U S A. 2002;99:10353–8.
92. Dunn EF, Pritlove DC, Elliott RM. The S RNA genome segments of Batai,
Cache Valley, Guaroa, Kairi, Lumbo, Main Drain and Northway bunyaviruses:
sequence determination and analysis. J Gen Virol. 1994;75:597–608.
93. Verbruggen P, Ruf M, Blakqori G, Overby AK, Heidemann M, Eick D, et al.
Interferon antagonist NSs of La Crosse virus triggers a DNA damage
response-like degradation of transcribing RNA polymerase II. J Biol Chem.
2011;286:3681–92.
94. Somesh BP, Reid J, Liu WF, Sogaard TM, Erdjument-Bromage H, Tempst P,
et al. Multiple mechanisms confining RNA polymerase II ubiquitylation to
polymerases undergoing transcriptional arrest. Cell. 2005;121:913–23.
95. Swanepoel R, Blackburn NK. Demonstration of nuclear immunofluorescence
in Rift Valley fever infected cells. J Gen Virol. 1977;34:557–61.
96. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, Makino S. Rift Valley
fever virus NSs protein promotes post-transcriptional downregulation of
protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog.
2009;5:e1000287.
97. Habjan M, Pichlmair A, Elliott RM, Overby AK, Glatter T, Gstaiger M, et al. NSs
protein of rift valley fever virus induces the specific degradation of the
double-stranded RNA-dependent protein kinase. J Virol. 2009;83:4365–75.
98. Gale Jr M, Tan SL, Katze MG. Translational control of viral gene expression in
eukaryotes. Microbiol Mol Biol Rev. 2000;64:239–80.
99. Langland JO, Cameron JM, Heck MC, Jancovich JK, Jacobs BL. Inhibition of
PKR by RNA and DNA viruses. Virus Res. 2006;119:100–10.
100. Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, et al. Impact of
protein kinase PKR in cell biology: from antiviral to antiproliferative action.
Microbiol Mol Biol Rev. 2006;70:1032–60.
101. Kalveram B, Lihoradova O, Indran SV, Lokugamage N, Head JA, Ikegami
T. Rift Valley fever virus NSs inhibits host transcription independently of
the degradation of dsRNA-dependent protein kinase PKR. Virology.
2013;435:415–24.
102. Mudhasani R, Tran JP, Retterer C, Kota KP, Whitehouse CA, Bavari S. Protein
Kinase R Degradation Is Essential for Rift Valley Fever Virus Infection and Is
Regulated by SKP1-CUL1-F-box (SCF)FBXW11-NSs E3 Ligase. PLoS Pathog.
2016;12:e1005437.
103. Kainulainen M, Lau S, Samuel CE, Hornung V, Weber F. NSs virulence factor
of Rift Valley fever virus engages the F-box proteins FBXW11 and beta-
TRCP1 to degrade the antiviral protein kinase PKR. J Virol. 2016;90:6140–7.
104. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases
for the treatment of cancer. Clin Cancer Res. 2009;15:3912–6.
105. Bridgen A, Weber F, Fazakerley JK, Elliott RM. Bunyamwera bunyavirus
nonstructural protein NSs is a nonessential gene product that contributes
to viral pathogenesis. Proc Natl Acad Sci U S A. 2001;98:664–9.
106. Blakqori G, Weber F. Efficient cDNA-based rescue of La Crosse bunyaviruses
expressing or lacking the nonstructural protein NSs. J Virol. 2005;79:10420–8.
107. Pettersson RF. Effect of Uukuniemi virus infection on host cell
macromolecule synthesis. Med Biol. 1974;52:90–7.
108. Brennan B, Li P, Zhang S, Li A, Liang M, Li D, et al. Reverse genetics system for
severe fever with thrombocytopenia syndrome virus. J Virol. 2015;89:3026–37.
109. Rezelj VV, Overby AK, Elliott RM. Generation of mutant Uukuniemi viruses
lacking the nonstructural protein NSs by reverse genetics indicates that NSs
is a weak interferon antagonist. J Virol. 2015;89:4849–56.
110. Eliseeva IA, Lyabin DN, Ovchinnikov LP. Poly(A)-binding proteins:
structure, domain organization, and activity regulation. Biochemistry
(Mosc). 2013;78:1377–91.
111. Copeland AM, Altamura LA, Van Deusen NM, Schmaljohn CS. Nuclear
relocalization of polyadenylate binding protein during rift valley fever virus
infection involves expression of the NSs gene. J Virol. 2013;87:11659–69.
112. Copeland AM, Van Deusen NM, Schmaljohn CS. Rift Valley fever virus NSS
gene expression correlates with a defect in nuclear mRNA export. Virology.
2015;486:88–93.
113. Blakqori G, van Knippenberg I, Elliott RM. Bunyamwera orthobunyavirus
S-segment untranslated regions mediate poly(A) tail-independent
translation. J Virol. 2009;83:3637–46.
114. Hussein IT, Mir MA. How hantaviruses modulate cellular pathways for
efficient replication? Front Biosci (Elite Ed). 2013;5:154–66.
115. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in
infectious disease. Nat Rev Immunol. 2015;15:87–103.
116. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising
cytokines with type I interferon-like properties. Cytokine Growth Factor
Rev. 2010;21:237–51.
117. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors:
biochemistry and biological functions. J Biol Chem. 2007;282:20053–7.
118. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma
and its receptor. Annu Rev Immunol. 1993;11:571–611.
119. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors
and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006;6:644–58.
120. Muller R, Saluzzo JF, Lopez N, Dreier T, Turell M, Smith J, et al. Characterization
of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus,
which is altered in the small segment. Am J Trop Med Hyg. 1995;53:405–11.
121. Bouloy M, Janzen C, Vialat P, Khun H, Pavlovic J, Huerre M, et al. Genetic
evidence for an interferon-antagonistic function of rift valley fever virus
nonstructural protein NSs. J Virol. 2001;75:1371–7.
122. Ermler ME, Yerukhim E, Schriewer J, Schattgen S, Traylor Z, Wespiser AR,
et al. RNA helicase signaling is critical for type i interferon production and
protection against Rift Valley fever virus during mucosal challenge. J Virol.
2013;87:4846–60.
123. Le May N, Mansuroglu Z, Leger P, Josse T, Blot G, Billecocq A, et al. A SAP30
complex inhibits IFN-beta expression in Rift Valley fever virus infected cells.
PLoS Pathog. 2008;4:e13.
124. Weill L, Shestakova E, Bonnefoy E. Transcription factor YY1 binds to the
murine beta interferon promoter and regulates its transcriptional capacity
with a dual activator/repressor role. J Virol. 2003;77:2903–14.
125. Head JA, Kalveram B, Ikegami T. Functional analysis of Rift Valley fever virus
NSs encoding a partial truncation. PLoS ONE. 2012;7:e45730.
126. Gori-Savellini G, Valentini M, Cusi MG. Toscana virus NSs protein inhibits the
induction of type I interferon by interacting with RIG-I. J Virol. 2013;87:6660–7.
127. Brisbarre NM, Plumet S, de Micco P, Leparc-Goffart I, Emonet SF. Toscana
virus inhibits the interferon beta response in cell cultures. Virology. 2013;
442:189–94.
128. Pifat DY, Smith JF. Punta Toro virus infection of C57BL/6 J mice: a model for
phlebovirus-induced disease. Microb Pathog. 1987;3:409–22.
129. Anderson Jr GW, Slayter MV, Hall W, Peters CJ. Pathogenesis of a
phleboviral infection (Punta Toro virus) in golden Syrian hamsters. Arch
Virol. 1990;114:203–12.
130. Perrone LA, Narayanan K, Worthy M, Peters CJ. The S segment of Punta
Toro virus (Bunyaviridae, Phlebovirus) is a major determinant of lethality in
the Syrian hamster and codes for a type I interferon antagonist. J Virol.
2007;81:884–92.
Ly and Ikegami Virology Journal  (2016) 13:118 Page 12 of 13
131. Mendenhall M, Wong MH, Skirpstunas R, Morrey JD, Gowen BB. Punta Toro
virus (Bunyaviridae, Phlebovirus) infection in mice: strain differences in
pathogenesis and host interferon response. Virology. 2009;395:143–51.
132. Ning YJ, Wang M, Deng M, Shen S, Liu W, Cao WC, et al. Viral suppression
of innate immunity via spatial isolation of TBK1/IKKepsilon from
mitochondrial antiviral platform. J Mol Cell Biol. 2014;6:324–37.
133. Ning YJ, Feng K, Min YQ, Cao WC, Wang M, Deng F, et al. Disruption of type
I interferon signaling by the nonstructural protein of severe fever with
thrombocytopenia syndrome virus via the hijacking of STAT2 and STAT1
into inclusion bodies. J Virol. 2015;89:4227–36.
134. Weber F, Bridgen A, Fazakerley JK, Streitenfeld H, Kessler N, Randall RE, et al.
Bunyamwera bunyavirus nonstructural protein NSs counteracts the
induction of alpha/beta interferon. J Virol. 2002;76:7949–55.
135. Kohl A, Clayton RF, Weber F, Bridgen A, Randall RE, Elliott RM. Bunyamwera
virus nonstructural protein NSs counteracts interferon regulatory factor
3-mediated induction of early cell death. J Virol. 2003;77:7999–8008.
136. Mansuroglu Z, Josse T, Gilleron J, Billecocq A, Leger P, Bouloy M, et al.
Non structural NSs protein of Rift Valley Fever Virus interacts with
pericentromeric DNA sequences of the host cell inducing chromosome
cohesion and segregation defects. J Virol. 2009;84:928–39.
137. Baer A, Austin D, Narayanan A, Popova T, Kainulainen M, Bailey C, et al.
Induction of DNA damage signaling upon Rift Valley fever virus
infection results in cell cycle arrest and increased viral replication. J Biol
Chem. 2012;287:7399–410.
138. McElroy AK, Nichol ST. Rift Valley fever virus inhibits a pro-inflammatory
response in experimentally infected human monocyte derived
macrophages and a pro-inflammatory cytokine response may be associated
with patient survival during natural infection. Virology. 2012;422:6–12.
139. Jansen van Vuren P, Shalekoff S, Grobbelaar AA, Archer BN, Thomas J,
Tiemessen CT, et al. Serum levels of inflammatory cytokines in Rift Valley
fever patients are indicative of severe disease. Virol J. 2015;12:159.
140. Benferhat R, Josse T, Albaud B, Gentien D, Mansuroglu Z, Marcato V, et al. Large-
scale chromatin immunoprecipitation with promoter sequence microarray
analysis of the interaction of the NSs protein of Rift Valley fever virus with
regulatory DNA regions of the host genome. J Virol. 2012;86:11333–44.
141. Palacios G, Tesh R, Travassos da Rosa A, Savji N, Sze W, Jain K, et al.
Characterization of the Candiru antigenic complex (Bunyaviridae:
Phlebovirus), a highly diverse and reassorting group of viruses affecting
humans in tropical America. J Virol. 2011;85:3811–20.
142. Palacios G, Wiley MR, Travassos da Rosa AP, Guzman H, Quiroz E, Savji N,
et al. Characterization of the Punta Toro species complex (genus
Phlebovirus, family Bunyaviridae). J Gen Virol. 2015;96:2079–85.
143. Palacios G, Savji N, Travassos da Rosa A, Desai A, Sanchez-Seco MP, Guzman
H, et al. Characterization of the Salehabad virus species complex of the
genus Phlebovirus (Bunyaviridae). J Gen Virol. 2013;94:837–42.
144. Palacios G, Tesh RB, Savji N, Travassos da Rosa AP, Guzman H, Bussetti AV,
et al. Characterization of the Sandfly fever Naples species complex and
description of a new Karimabad species complex (genus Phlebovirus, family
Bunyaviridae). J Gen Virol. 2014;95:292–300.
145. Palacios G, Savji N, Travassos da Rosa A, Guzman H, Yu X, Desai A, et al.
Characterization of the Uukuniemi virus group (Phlebovirus: Bunyaviridae):
evidence for seven distinct species. J Virol. 2013;87:3187–95.
146. Matsuno K, Weisend C, Travassos da Rosa AP, Anzick SL, Dahlstrom E,
Porcella SF, et al. Characterization of the Bhanja serogroup viruses
(Bunyaviridae): a novel species of the genus Phlebovirus and its relationship
with other emerging tick-borne phleboviruses. J Virol. 2013;87:3719–28.
147. Xu F, Liu D, Nunes MR, DA Rosa AP, Tesh RB, Xiao SY. Antigenic and genetic
relationships among Rift Valley fever virus and other selected members of the
genus Phlebovirus (Bunyaviridae). Am J Trop Med Hyg. 2007;76:1194–200.
148. Palacios G, da Rosa AT, Savji N, Sze W, Wick I, Guzman H, et al. Aguacate
virus, a new antigenic complex of the genus Phlebovirus (family
Bunyaviridae). J Gen Virol. 2011;92:1445–53.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ly and Ikegami Virology Journal  (2016) 13:118 Page 13 of 13
